NEOG

Business Context and Reporting Period

Company: Neogen Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: May 31, 2005
Business Overview: Neogen develops, manufactures, and markets products dedicated to food and animal safety. Operations are divided into two primary segments: Food Safety (diagnostic test kits for pathogens, toxins, and allergens) and Animal Safety (pharmaceuticals, rodenticides, vaccines, and veterinary instruments). The company operates manufacturing facilities in the U.S. (Michigan, Kentucky, Wisconsin, Florida) and the U.K. (Scotland).

Key Financial Metrics (Fiscal Year 2005)

Segment Performance:

• Food Safety: $28.2 million (44.9% of total revenue), up 2% year-over-year.
• Animal Safety: $34.6 million (55.1% of total revenue), up 24% year-over-year.

Material Changes vs. Prior Period

• Revenue Growth: Consolidated revenue increased 13% to $62.8 million, driven primarily by the Animal Safety segment (up 24%). The Food Safety segment grew modestly by 2%.
• Profitability: Net income rose 16% to $5.9 million, outpacing revenue growth due to improved product mix, cost controls, and the integration of prior acquisitions.
• Debt Reduction: The company repaid the remaining $3.9 million of its credit facility during the year, resulting in zero long-term debt as of May 31, 2005.
• Acquisition Impact: The 2003 acquisitions of Hacco, Inc. and Hess & Clark, Inc. contributed significantly to Animal Safety growth, with rodenticide and disinfectant sales increasing 116% due to a full year of operations compared to a partial year in 2004.
• Product Mix Shift: Food Safety margins were impacted by the transition of ATP sanitation testing from an outside supplier to an internally produced product, which initially reduced sales volume but is expected to improve long-term margins.

Guidance, Outlook, and Risks

Management Commentary:

• Management does not provide specific financial forecasts but remains optimistic about long-term prospects.
• Strategy focuses on organic growth, international expansion, and strategic acquisitions.
• Research and Development (R&D) expenditures were $2.7 million (4% of revenue); management intends to maintain R&D at 5-6% of total revenue.

Recent Developments & Contingencies:

• Acquisition: On July 1, 2005, Neogen signed an agreement to acquire UCB S.A.'s dairy antibiotic testing business for $14.7 million in cash. Closing is expected late in calendar year 2005.
• Capital Needs: While the company is profitable with positive cash flow, management notes that current funds may not be sufficient for future commercialization or acquisitions, potentially requiring equity issuance or additional financing.

Risks:

• Regulatory: Significant portion of products subject to USDA and FDA regulations; changes could affect costs or production.
• Competition: Intense competition in both food and animal safety markets from companies with greater financial resources.
• Foreign Operations: Exposure to currency fluctuations, import/export duties, and political changes in foreign markets (27% of revenue is international).
• Patent Protection: Reliance on patents and trade secrets; potential litigation or inability to secure licenses could hinder product sales.

Investor Verification Checklist

• Acquisition Integration: Verify the successful integration and margin improvement of the internally produced ATP sanitation product in the Food Safety segment.
• Debt Capacity: Confirm the status of the $15 million revolving credit line and the company's ability to fund the pending $14.7 million UCB acquisition without diluting shareholders.
• International Growth: Assess the sustainability of the 27% international revenue contribution given currency and regulatory risks.
• Goodwill Valuation: Review the annual impairment test results for goodwill ($18.6 million) and intangible assets, particularly given the heavy reliance on acquisitions for growth.
• Regulatory Approvals: Monitor the status of FDA approval for the Beta Star test (part of the UCB acquisition) for the U.S. dairy market.